Suzetrigine (VX-548, Journavx®), the first-in-class oral NaV1.8 inhibitor developed by Vertex Pharmaceuticals and approved by the FDA in January 2025, was named Molecule of the Year 2024 by Drug Hunter.
To support further exploration of NaV1.8 channel inhibition as a novel analgesic strategy, we have designed a focused set of suzetrigine analogs: https://chem-space.com/list/3f51ed6924c34b5d82a3382a283dd259
The NaV1.8 voltage-gated sodium channel plays a critical role in pain signal transduction. Through selective targeting, suzetrigine provides effective pain relief without the CNS-related side effects or addiction risks associated with opioids. Clinical trials have demonstrated significant pain reduction across multiple acute pain conditions with a favorable safety profile, which highlights NaV1.8 as a validated target for next-generation analgesics.
We welcome collaborations to evaluate suzetrigine analogs further and explore new therapeutic opportunities in pain research. For orders and inquiries, contact us at [email protected].
